Notice of annual meeting.
The Reagan-Udall Foundation for the Food and Drug Administration (FDA), which was created by Title VI of the Food and Drug Amendments of 2007, is announcing an annual open public meeting. The Foundation will provide an overview of its history, project updates, as well as projected activities going forward.
The open public meeting will be held on May 14, 2014, from 10 a.m. until 12 p.m. Interested persons may sign up to attend in person and/or make comments at the meeting or submit written comments by visiting http://www.ReaganUdall.org on or before May 6, 2014. Oral comments from the public will be scheduled between approximately 11 a.m. and 12 p.m. Time allotted for each registrant will be 3 minutes. The contact person will notify interested persons regarding their request to speak by May 9, 2014. Written comments are encouraged. Those individuals interested in making formal comments should notify the contact person and submit a brief statement of the general nature of the comments they wish to present. Written comments are encouraged through May 12, 2014.
The public meeting will be held at 901 East Conference Center, The Pew Charitable Trusts, 901 East St. NW., Washington, DC 20004.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Jane Reese-Coulbourne, Reagan-Udall Foundation for the FDA, 202-828-1206, Meetings@ReaganUdall.org.
End Further Info
Start Supplemental Information
The Reagan-Udall Foundation for the FDA (the Foundation) is an independent 501(c)(3) not-for-profit organization Start Printed Page 18739created by Congress to advance the mission of FDA to modernize medical, veterinary, food, food ingredient, and cosmetic product development; accelerate innovation; and enhance product safety. With the ultimate goal of improving public health, the Foundation provides a unique opportunity for different sectors (FDA, patient groups, academia, other government entities, and industry) to work together in a transparent way to create exciting new research projects to advance regulatory science.
The Foundation acts as a neutral third party to establish novel, scientific collaborations. Much like any other independently developed information, FDA evaluates the scientific information from these collaborations to determine how Reagan-Udall Foundation projects can help the Agency to fulfill its mission.
The Foundation's projects include: The Innovation in Medical Evidence Development and Surveillance (IMEDS) Program, methods for using observational electronic health care data for postmarket evidence generation, including postmarket safety surveillance; the Systems Toxicology Project, an evaluation of a systems biology approach to preclinical safety testing; and the Critical Path to Tuberculosis Multidrug Regimens (CPTR) Project, looking at new ways to develop tuberculosis combination therapies. The Foundation seeks comments on these and other potential topics for future activities.
The Foundation will be providing an overview of its history, project updates, as well as projected activities going forward. Find the Meeting Agenda at http://www.ReaganUdall.org.
End Supplemental Information
Dated: March 31, 2014.
Executive Director, Reagan-Udall Foundation for the FDA.
[FR Doc. 2014-07484 Filed 4-2-14; 8:45 am]
BILLING CODE 4164-04-P